ReviewPharmacoEconomics2019

Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.

Ros Wade et al.PubMed ↗Publisher ↗

No numbers read from the abstract.